NewEdge Advisors’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3,225
Closed -$39.8K 3825
2023
Q3
$39.8K Sell
3,225
-330
-9% -$33.9K ﹤0.01% 2158
2023
Q2
$123K Buy
+3,555
New +$443K ﹤0.01% 1785
2023
Q1
Sell
-50
Closed -$60 3831
2022
Q4
$60 Buy
+50
New +$6.97K ﹤0.01% 3443

Other funds holding LABU

NewEdge Advisors's LABU Position: Q4 2023 in Review

NewEdge Advisors sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q4 2023, closing a stake of 3,225 shares — an estimated $39.8K sold.

NewEdge Advisors first reported a position in LABU in Q4 2022 and held it in 3 quarters. The position peaked at $123K in Q2 2023. 41 funds tracked by Wall St. Rank hold LABU as of Q4 2023.

  • NewEdge Advisors reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q4 2023 after selling out during the quarter.
  • NewEdge Advisors sold 3,225 Direxion Daily S&P Biotech Bull 3X ETF shares in Q4 2023, an estimated $39.8K.
  • NewEdge Advisors first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2022 and held it in 3 quarters.
  • NewEdge Advisors's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $123K in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q4 2023.

Based on NewEdge Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.